BILLERICA, Mass. , July 14, 2021 (GLOBE NEWSWIRE) -- Conformis , Inc. (NASDAQ: CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti , Chief Executive Officer, and Bob Howe , Chief Financial Officer, will present

Conformis Settles Wright Medical Litigation Related to Patient-Specific Instruments for Use with Shoulder Implants BILLERICA, Mass. , July 07, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it has entered into a settlement with Stryker Corporation (“Stryker”) resolving

BILLERICA, Mass. , July 01, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will release its financial results for the second quarter ended June 30, 2021 after the market closes on August 4, 2021 at approximately 4:00 p.m. Eastern Time .

New Agreement expands Conformis’ global reach and brings patient-specific knee replacement systems to the largest market in the Asia-Pacific region BILLERICA, Mass. , June 23, 2021 (GLOBE NEWSWIRE) -- Conformis , Inc. (NASDAQ:CFMS) today announced the execution of an agreement to enter the

BILLERICA, Mass. , May 18, 2021 (GLOBE NEWSWIRE) -- Conformis , Inc. (NASDAQ: CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti , Chief Executive Officer, will present at the Oppenheimer MedTech, Tools &

BILLERICA, Mass. , May 12, 2021 (GLOBE NEWSWIRE) -- Conformis , Inc. (NASDAQ: CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti , Chief Executive Officer, and Bob Howe , Chief Financial Officer, will present

Leveraging Conformis’ extensive library of personalized knee design data and patient images, Identity Imprint is designed to match patients’ anatomy with an optimal arthroplasty solution while at the same time offering greater efficiency, cost savings, increased intraoperative flexibility, and

BILLERICA, Mass. , May 05, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the first quarter ended March 31, 2021 .

BILLERICA, Mass. , April 22, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it received 510(k) clearance by the U.S. Food and Drug Administration for patient-specific instrumentation (“PSI”) developed by the Company under its License Agreement and Development Agreement

Commercial Interest in Accurate, Disposable, Patient-Specific Instrumentation Continues to Expand BILLERICA, Mass. , April 19, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it has entered into a license agreement with Paragon 28, Inc., granting Paragon 28 a

BILLERICA, Mass. , April 07, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will release its financial results for the first quarter ended March 31, 2021 after the market closes on May 5, 2021 at approximately 4:00 p.m. Eastern Time .

Independent, retrospective review of 2016-2019 surgeon data by University of Washington researchers demonstrates that Conformis iTotal® knee replacement implants enable expedited surgical time and reduce length of hospital stay. BILLERICA, Mass. , March 16, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc.

BILLERICA, Mass. , March 03, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today financial results for the fourth quarter and year ended December 31, 2020 . Fourth Quarter 2020 Summary Total revenue of $16.7 million , a decrease of 16% year-over-year on a reported basis and 17%

The iTotal® PS total knee replacement system is designed so that its patient-specific implants fit the unique size and shape of each patient’s knee, and provide optimal stability throughout the full range of motion BILLERICA, Mass. , March 01, 2021 (GLOBE NEWSWIRE) -- Conformis , Inc. (NASDAQ:

BILLERICA, Mass. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Conformis , Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti , Chief Executive Officer, and Bob Howe , Chief Financial Officer, will participate

BILLERICA, Mass. , Feb. 12, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (Nasdaq: CFMS) today announced it has priced an underwritten public offering of 80,952,381 shares of its common stock at an offering price of $1.05 per share. The gross proceeds from the offering will be approximately $85 million

BILLERICA, Mass. , Feb. 11, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (Nasdaq: CFMS) today announced that it intends to offer shares of its common stock in an underwritten public offering. Conformis intends to grant the underwriters a 30-day option to purchase additional shares of its common stock

BILLERICA, Mass. and COLUMBIA CITY, Ind. , Jan. 21, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) and SITES Medical, a firm dedicated to inventing and de-risking new orthopedic medical device technologies, today announced they have entered into a non-exclusive development and supply

BILLERICA, Mass. , Jan. 07, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will release its financial results for the fourth quarter and fiscal year ended December 31, 2020 after the market closes on March 3, 2021 at approximately 4:00 p.m. Eastern Time .